Reliability of the Lymph Node Ratio in the Prediction of Gastric Cancer Survival

Background. Lymph node metastasis is the major determinant factor in the prognosis of gastric cancer. There is still no definite consensus on the lymph node number that should be harvested during gastric cancer surgery. Lymph Node Ratio (LNR) is defined as the ratio of metastatic nodes to the total number of pathologically examined lymph nodes. LNR has been proposed to be a sensitive prognostic factor in patients with gastric cancer. In this study the reliability of the LNR is tested for being a prognostic factor in gastric cancer survival. Methods. Medical records of 244 patients, with neither distant metastases nor neoadjuvant treatment underwent curative gastrectomy, were analyzed retrospectively in terms of survival according to the lymph node ratio (LNR). Patients were divided in two groups by using LNR cut-off value. Results. LNR of 0.4 was proved to be the best cut-off value to predict the prognosis of patients with gastric cancer. Univariate and multivariate analysis revealed that age over 65 (p < 0.001), and LNR ≥ 0.4 (p = 0.02) were independent factors in gastric cancer survival. Patients with LNR ≥ 0.4 presented with worse outcomes regarding other prognostic parameters (tumor differentiation, tumor diameter, lymphovascular invasion or perineural invasion), despite similar numbers of lymph nodes being harvested in both groups during surgery. Conclusion. Lymph node ratio is a reliable parameter to predict the survival in gastric cancer.

[1]  A. Senger,et al.  Prognostic significance of the metastatic lymph node ratio compared to the TNM classification in stage III gastric cancer , 2021, Nigerian journal of clinical practice.

[2]  Jia Wei,et al.  Prognostic Nomograms Based on Three Lymph Node Classification Systems for Resected Gastric Adenocarcinoma: A Large Population-Based Cohort Study and External Validation , 2021, Annals of Surgical Oncology.

[3]  J. Ajani,et al.  Benchmarks for nodal yield and ratio for node-positive gastric cancer. , 2021, Surgery.

[4]  B. Badgwell,et al.  Current treatment and recent progress in gastric cancer , 2021, CA: a cancer journal for clinicians.

[5]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[6]  M. Kanda,et al.  Accurate Risk Stratification of Patients with Node-Positive Gastric Cancer by Lymph Node Ratio , 2020, World Journal of Surgery.

[7]  H. Hoshi Management of Gastric Adenocarcinoma for General Surgeons. , 2020, The Surgical clinics of North America.

[8]  T. Yoshikawa,et al.  Association Between Lymph Node Ratio and Survival in Patients with Pathological Stage II/III Gastric Cancer , 2020, Annals of Surgical Oncology.

[9]  S. Cai,et al.  Young age increases risk for lymph node positivity in gastric cancer: A Chinese multi-institutional database and US SEER database study , 2020, Journal of Cancer.

[10]  G. Yaprak,et al.  Prognostic factors for survival in patients with gastric cancer: Single-centre experience , 2019, Northern clinics of Istanbul.

[11]  Z-P Tan Recent Advances in the Surgical Treatment of Advanced Gastric Cancer: A Review , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[12]  J. Chen,et al.  Prognostic significance of metastatic lymph node ratio: the lymph node ratio could be a prognostic indicator for patients with gastric cancer , 2018, World Journal of Surgical Oncology.

[13]  Hui-mian Xu,et al.  Development of a risk-scoring system to evaluate the serosal invasion for macroscopic serosal invasion positive gastric cancer patients. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  M. Tez,et al.  The prognostic value of different node staging systems in patients with ≤15 lymph nodes following surgery for gastric adenocarcinoma , 2018, Acta chirurgica Belgica.

[15]  H. Weir,et al.  The TNM classification of malignant tumours-towards common understanding and reasonable expectations. , 2017, The Lancet. Oncology.

[16]  Ping Li,et al.  Differences in the multimodal treatment of gastric cancer: East versus west , 2017, Journal of surgical oncology.

[17]  D. Ichikawa,et al.  Positive Lymph Node Ratio as an Indicator of Prognosis and Local Tumor Clearance in N3 Gastric Cancer , 2016, Journal of Gastrointestinal Surgery.

[18]  P. Coffer,et al.  Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. , 2013, Immunity.

[19]  Ji-hoon Kim,et al.  Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection , 2013, Gastric Cancer.

[20]  F. Sarkar,et al.  Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway , 2013, Journal of Translational Medicine.

[21]  H. Lee,et al.  Undifferentiated-type gastric adenocarcinoma: prognostic impact of three histological types , 2012, World Journal of Surgical Oncology.

[22]  K. Bickenbach,et al.  Comparisons of Gastric Cancer Treatments: East vs. West , 2012, Journal of gastric cancer.

[23]  Atilla Kurt,et al.  Guidelines for Extended Lymphadenectomy in Gastric Cancer: A Prospective Comparative Study , 2012, Annals of Surgical Oncology.

[24]  L. Jacks,et al.  Comparison of Gastric Cancer Survival Following R0 Resection in the United States and Korea Using an Internationally Validated Nomogram , 2010, Annals of surgery.

[25]  Y. Sugiyama,et al.  Prognostic Significance of the Metastatic Lymph Node Ratio in Gastric Cancer Patients , 2009, World Journal of Surgery.

[26]  Quentin Liu,et al.  Positive Lymph Node Ratio Is an Independent Prognostic Factor in Gastric Cancer After D2 Resection Regardless of the Examined Number of Lymph Nodes , 2009, Annals of Surgical Oncology.

[27]  S. Mocellin,et al.  The prognostic value of N-ratio in patients with gastric cancer: validation in a large, multicenter series. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  S. Fushida,et al.  Outcome of ratio of lymph node metastasis in gastric carcinoma , 2002, Annals of Surgical Oncology.

[29]  David D. Smith,et al.  Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Mitsuru Sasako,et al.  Determining prognostic factors for gastric cancer using the regression tree method , 2002, Gastric Cancer.

[31]  D. Gouma,et al.  Extended lymph-node dissection for gastric cancer. , 1999, The New England journal of medicine.

[32]  S. Kim,et al.  Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer , 1998, Gastric Cancer.